User menu

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.

Bibliographic reference Machiels, Jean-Pascal ; Licitra, Lisa F ; Haddad, Robert I ; Tahara, Makoto ; Cohen, Ezra Ew. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.. In: BMC Cancer, Vol. 14, no.1, p. 473 (2014)
Permanent URL http://hdl.handle.net/2078.1/147206
  1. GLOBOCAN: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2008, http://www.globocan.iarc.fr ,
  2. Seiwert Tanguy Y, Salama Joseph K, Vokes Everett E, The chemoradiation paradigm in head and neck cancer, 10.1038/ncponc0750
  3. Huguenin Pia, Beer Karl T., Allal Abdelkarim, Rufibach Kaspar, Friedli Corinne, Davis Jacques Bernard, Pestalozzi Bernhard, Schmid Stephan, Thöni Armin, Ozsahin Mahmut, Bernier Jacques, Töpfer Michael, Kann Roger, Meier Urs Richard, Thum Peter, Bieri Sabine, Notter Markus, Lombriser Norbert, Glanzmann Christoph, Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy, 10.1200/jco.2004.12.193
  4. Pan Quintin, Gorin Michael A, Teknos Theodoros N, Pharmacotherapy of head and neck squamous cell carcinoma, 10.1517/14656560903136754
  5. Bernier Jacques, Domenge Christian, Ozsahin Mahmut, Matuszewska Katarzyna, Lefèbvre Jean-Louis, Greiner Richard H., Giralt Jordi, Maingon Philippe, Rolland Frédéric, Bolla Michel, Cognetti Francesco, Bourhis Jean, Kirkpatrick Anne, van Glabbeke Martine, Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer, 10.1056/nejmoa032641
  6. Vermorken Jan B., Mesia Ricard, Rivera Fernando, Remenar Eva, Kawecki Andrzej, Rottey Sylvie, Erfan Jozsef, Zabolotnyy Dmytro, Kienzer Heinz-Roland, Cupissol Didier, Peyrade Frederic, Benasso Marco, Vynnychenko Ihor, De Raucourt Dominique, Bokemeyer Carsten, Schueler Armin, Amellal Nadia, Hitt Ricardo, Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer, 10.1056/nejmoa0802656
  7. NCCN: Clinical Practice Guidelines in Oncology. Head and Neck Cancer. V 1.2012. 2012, 2012: 2012, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp ,
  8. Clavel M., Vermorken J. B., Cognetti F., Cappelaere P., Mulder P. H. M.de, Schornagel J. H., Tueni E. A., Verweij J., Wildiers J., Clerico M., Dalesio O., Kirkpatrick A., Snow G. B., Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck, 10.1093/oxfordjournals.annonc.a058906
  9. Forastiere A A, Metch B, Schuller D E, Ensley J F, Hutchins L F, Triozzi P, Kish J A, McClure S, VonFeldt E, Williamson S K, Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study., 10.1200/jco.1992.10.8.1245
  10. Jacobs C, Lyman G, Velez-García E, Sridhar K S, Knight W, Hochster H, Goodnough L T, Mortimer J E, Einhorn L H, Schacter L, A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck., 10.1200/jco.1992.10.2.257
  11. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck : The Liverpool Head and Neck Oncology Group, 10.1038/bjc.1990.59
  12. Forastiere AA, Leong T, Murphy B: A phase III trial of high-dose paclitaxel and cisplatin and G-CSF versus low-dose paclitaxel and cisplatin in patients with advanced squamous cell carcinoma of the head and neck: an ECOG group trial. Proc Am Soc Clin Oncol. 1997, 16: 1367-
  13. Thodtmann R., Theiss F., Kemmerich M., Heinrich B., Laubenbacher C., Quasthoff S., Kau R., Herzog M., Diergarten K., Hanauske A.-R., Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck, 10.1023/a:1008298915121
  14. Gibson Michael K., Li Yi, Murphy Barbara, Hussain Maha H.A., DeConti Ronald C., Ensley John, Forastiere Arlene A., Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group, 10.1200/jco.2005.01.057
  15. Schornagel J H, Verweij J, de Mulder P H, Cognetti F, Vermorken J B, Cappelaere P, Armand J P, Wildiers J, de Graeff A, Clavel M, Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study., 10.1200/jco.1995.13.7.1649
  16. Stewart J. Simon W., Cohen Ezra E.W., Licitra Lisa, Van Herpen Carla M.L., Khorprasert Chonlakiet, Soulieres Denis, Vodvarka Pavel, Rischin Danny, Garin Avgust M., Hirsch Fred R., Varella-Garcia Marileila, Ghiorghiu Serban, Hargreaves Laura, Armour Alison, Speake Georgina, Swaisland Alan, Vokes Everett E., Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2008.17.0530
  17. Machiels Jean-Pascal, Subramanian Somasundaram, Ruzsa Agnes, Repassy Gabor, Lifirenko Igor, Flygare Annika, Sørensen Per, Nielsen Tina, Lisby Steen, Clement Paul MJ, Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial, 10.1016/s1470-2045(11)70034-1
  18. Hong Waun Ki, Schaefer Steven, Issell Brian, Cummings Charles, Luedke Daniel, Bromer Richard, Fofonoff Stephanie, D'Aoust Joan, Shapshay Stanley, Welch Janet, Levin Elizabeth, Vincent Miriam, Vaughan Charles, Strong Stuart, A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck, 10.1002/1097-0142(19830715)52:2<206::aid-cncr2820520204>3.0.co;2-j
  19. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ: Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study. Cancer Treat Rep. 1985, 69: 577-581.
  20. Guardiola E., Peyrade F., Chaigneau L., Cupissol D., Tchiknavorian X., Bompas E., Madroszyk A., Ronchin P., Schneider M., Bleuze J.P., Blay J.Y., Pivot X., Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer, 10.1016/j.ejca.2004.05.019
  21. Nicholson R.I, Gee J.M.W, Harper M.E, EGFR and cancer prognosis, 10.1016/s0959-8049(01)00231-3
  22. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G, Mancuso S, Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma, 10.1038/bjc.1996.525
  23. Bristol-Myers Squibb/Eli Lilly: Erbitux® (cetuximab). Prescribing Information. http://packageinserts.bms.com/pi/pi_erbitux.pdf ,
  24. Merck Serono: Erbitux® (cetuximab). Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/19595/SPC/Erbitux+5mg+ml+solution+for+infusion/ ,
  25. Burtness Barbara, Goldwasser Meredith A., Flood William, Mattar Bassam, Forastiere Arlene A., Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study, 10.1200/jco.2005.02.4646
  26. Herbst Roy S., Arquette Matthew, Shin Dong M., Dicke Karel, Vokes Everett E., Azarnia Nozar, Hong Waun Ki, Kies Merrill S., Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2005.07.120
  27. Baselga José, Trigo José M., Bourhis Jean, Tortochaux Jacques, Cortés-Funes Hernán, Hitt Ricardo, Gascón Pere, Amellal Nadia, Harstrick Andreas, Eckardt André, Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck, 10.1200/jco.2005.07.119
  28. Vermorken Jan B., Trigo José, Hitt Ricardo, Koralewski Piotr, Diaz-Rubio Eduardo, Rolland Frédéric, Knecht Rainald, Amellal Nadia, Schueler Armin, Baselga José, Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy, 10.1200/jco.2006.06.7447
  29. León X., Hitt R., Constenla M., Rocca A., Stupp R., Kovács A.F., Amellal N., Bessa E.H., Bourhis J., A Retrospective Analysis of the Outcome of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Refractory to a Platinum-based Chemotherapy, 10.1016/j.clon.2005.02.014
  30. Vermorken Jan. B., Herbst Roy S., Leon Xavier, Amellal Nadia, Baselga Jose, Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies, 10.1002/cncr.23442
  31. Elferink Lisa A., Resto Vicente A., Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer, 10.1155/2011/982879
  32. Agulnik Mark, New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN), 10.1007/s12032-012-0159-2
  33. Solca F., Dahl G., Zoephel A., Bader G., Sanderson M., Klein C., Kraemer O., Himmelsbach F., Haaksma E., Adolf G. R., Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, 10.1124/jpet.112.197756
  34. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac L R, Padera R F, Shapiro G I, Baum A, Himmelsbach F, Rettig W J, Meyerson M, Solca F, Greulich H, Wong K-K, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, 10.1038/onc.2008.109
  35. Sequist Lecia V., Yang James Chih-Hsin, Yamamoto Nobuyuki, O'Byrne Kenneth, Hirsh Vera, Mok Tony, Geater Sarayut Lucien, Orlov Sergey, Tsai Chun-Ming, Boyer Michael, Su Wu-Chou, Bennouna Jaafar, Kato Terufumi, Gorbunova Vera, Lee Ki Hyeong, Shah Riyaz, Massey Dan, Zazulina Victoria, Shahidi Mehdi, Schuler Martin, Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations, 10.1200/jco.2012.44.2806
  36. BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC): BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-Small Cell Lung Cancer (NSCLC). 2992, http://www.clinicaltrials.gov/ct2/show/NCT01121393 , (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-Small Cell Lung Cancer (NSCLC),
  37. LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of The Lung. http://www.clinicaltrials.gov/ct2/show/NCT01466660?term=NCT01466660&rank=1 ,
  38. Yang James Chih-Hsin, Shih Jin-Yuan, Su Wu-Chou, Hsia Te-Chun, Tsai Chun-Ming, Ou Sai-Hong Ignatius, Yu Chung-Jen, Chang Gee-Chen, Ho Ching-Liang, Sequist Lecia V, Dudek Arkadiusz Z, Shahidi Mehdi, Cong Xiuyu Julie, Lorence Robert M, Yang Pan-Chyr, Miller Vincent A, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial, 10.1016/s1470-2045(12)70086-4
  39. Miller Vincent A, Hirsh Vera, Cadranel Jacques, Chen Yuh-Min, Park Keunchil, Kim Sang-We, Zhou Caicun, Su Wu-Chou, Wang Mengzhao, Sun Yan, Heo Dae Seog, Crino Lucio, Tan Eng-Huat, Chao Tsu-Yi, Shahidi Mehdi, Cong Xiuyu Julie, Lorence Robert M, Yang James Chih-Hsin, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, 10.1016/s1470-2045(12)70087-6
  40. Murakami H., Tamura T., Takahashi T., Nokihara H., Naito T., Nakamura Y., Nishio K., Seki Y., Sarashina A., Shahidi M., Yamamoto N., Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4), 10.1007/s00280-011-1738-1
  41. Schuler MH, Planchard D, Yang JC-H, Kim J-H, De Marinis F, Chen Y-M, Zhou C, Bennouna J, Liu X, Feng JF, Bidoli P, Strausz J, Ou S-HI, Chand VK, Wang B, Munzert GM, Park K: Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy [abstract]. J Clin Oncol. 2012, 30: 7557-
  42. Katakami Nobuyuki, Atagi Shinji, Goto Koichi, Hida Toyoaki, Horai Takeshi, Inoue Akira, Ichinose Yukito, Koboyashi Kunihiko, Takeda Koji, Kiura Katsuyuki, Nishio Kazuto, Seki Yoko, Ebisawa Ryuichi, Shahidi Mehdi, Yamamoto Nobuyuki, LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both, 10.1200/jco.2012.45.0981
  43. LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy. http://www.clinicaltrials.gov/ct2/show/NCT01523587?term=NCT01523587&rank=1 ,
  44. Yang JC-H, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O’Brien O, Wolf J, Cohen E: Gastrointestinal adverse events associated with afatinib, an oral ErbB family blocker. Oncologist. 2013, In press
  45. Lacouture M, Schadendorf D, Chu C-Y, Uttenreuther-Fischer M, Stammberger U, O’Brien D, Hauschildg A: Dermatologic adverse events associated with Afatinib, an oral ErbB family blocker. Oncologist. 2013, In press
  46. Schütze Christina, Dörfler Annegret, Eicheler Wolfgang, Zips Daniel, Hering Sandra, Solca Flavio, Baumann Michael, Krause Mechthild, Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma, 10.1007/s00066-007-1696-z
  47. Solca F., Baum A., Krause M., Baumann M., Wong K.K., Greulich H., Adolf G., 5508 POSTER Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer, 10.1016/s1359-6349(07)71225-9
  48. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE: A randomized, phase 2 study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014, Epub ahead of print
  49. Cupissol D, Seiwert TY, Fayette J, Ehrnrooth E, Blackman A, Cong XJ, Cohen EEW: A randomized, open-label, phase II study of afatinib vs cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of stage 2 (S2) following crossover [abstract]. J Clin Oncol. 2013, 31: 6001-
  50. Eskens F A L M, Mom C H, Planting A S T, Gietema J A, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries E G E, A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours, 10.1038/sj.bjc.6604108
  51. Gordon Michael S., Mendelson David S., Gross Mitchell, Uttenreuther-Fischer Martina, Ould-Kaci Mahmoud, Zhao Yihua, Stopfer Peter, Agus David B., A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors, 10.1007/s10637-012-9904-9